Voyager Therapeutics (NASDAQ:VYGR) Earns “Buy” Rating from HC Wainwright

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $30.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 431.91% from the company’s previous close.

Several other analysts also recently weighed in on the company. Leerink Partners started coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price for the company. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, November 10th. Finally, Wedbush reduced their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Voyager Therapeutics has an average rating of “Moderate Buy” and an average price target of $17.00.

Voyager Therapeutics Price Performance

Shares of VYGR opened at $5.64 on Thursday. Voyager Therapeutics has a 1-year low of $5.59 and a 1-year high of $11.72. The stock has a market cap of $308.11 million, a PE ratio of 7.94 and a beta of 0.89. The firm has a fifty day moving average price of $6.62 and a 200 day moving average price of $7.50.

Insider Transactions at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the transaction, the insider now owns 86,001 shares of the company’s stock, valued at $500,525.82. This represents a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Institutional investors have recently made changes to their positions in the stock. Barclays PLC lifted its stake in shares of Voyager Therapeutics by 55.8% in the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after purchasing an additional 37,398 shares during the period. Erste Asset Management GmbH purchased a new stake in shares of Voyager Therapeutics during the 3rd quarter worth approximately $6,192,000. Verition Fund Management LLC acquired a new stake in shares of Voyager Therapeutics in the 3rd quarter worth approximately $216,000. BNP Paribas Financial Markets increased its stake in Voyager Therapeutics by 30.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 49,235 shares of the company’s stock valued at $288,000 after purchasing an additional 11,516 shares in the last quarter. Finally, FMR LLC boosted its position in Voyager Therapeutics by 26.9% during the third quarter. FMR LLC now owns 92,498 shares of the company’s stock worth $541,000 after purchasing an additional 19,622 shares in the last quarter. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.